81OERLOTINIB AS NEOADJUVANT TREATMENT IN ENDOBRONCHIAL ULTRASOUND CONFIRMED STAGE IIIA-N2 NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION (EXON 19 OR 21) (NCT01217619, ESTERN): A PROSPECTIVE, SINGLE ARM, PHASE II CLINICAL TRIAL